[go: up one dir, main page]

MX2007004079A - Detecci??n de niveles elevados de prote??na her-2/neu en celulas cancerosas circulantes y tratamiento. - Google Patents

Detecci??n de niveles elevados de prote??na her-2/neu en celulas cancerosas circulantes y tratamiento.

Info

Publication number
MX2007004079A
MX2007004079A MX2007004079A MX2007004079A MX2007004079A MX 2007004079 A MX2007004079 A MX 2007004079A MX 2007004079 A MX2007004079 A MX 2007004079A MX 2007004079 A MX2007004079 A MX 2007004079A MX 2007004079 A MX2007004079 A MX 2007004079A
Authority
MX
Mexico
Prior art keywords
neu
cancer cells
treatment
detection
protein levels
Prior art date
Application number
MX2007004079A
Other languages
English (en)
Inventor
Robert M Lorence
Ming Lu
Original Assignee
Wellstat Biologics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Biologics Corp filed Critical Wellstat Biologics Corp
Publication of MX2007004079A publication Critical patent/MX2007004079A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G01N33/57515—
    • G01N33/57585—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La expresion de la proteina Her-2/neu en celulas cancerosas circulantes en una muestra de sangre es detectada por el aislamiento de las celulas cancerosas de la muestra de sangre y luego la realizacion en las celulas cancerosas aisladas de un inmunoensayo de Her-2/neu sensible. Un resultado positivo indica la expresion de Her- 2/neu en celulas cancerosas en la muestra de sangre. Este metodo se puede utilizar para identificar a pacientes con cancer quienes es probable que se beneficien del tratamiento con un agente carcinostatico que fija como objetivo la Her-2/neu, tal como trastuzumab (HERCEPTINA).
MX2007004079A 2004-10-06 2005-10-06 Detecci??n de niveles elevados de prote??na her-2/neu en celulas cancerosas circulantes y tratamiento. MX2007004079A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61633204P 2004-10-06 2004-10-06
PCT/US2005/035894 WO2006041959A2 (en) 2004-10-06 2005-10-06 Detection of elevated levels of her-2/neu protein on circulating cancer cells and treatment

Publications (1)

Publication Number Publication Date
MX2007004079A true MX2007004079A (es) 2007-06-15

Family

ID=36148887

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007004079A MX2007004079A (es) 2004-10-06 2005-10-06 Detecci??n de niveles elevados de prote??na her-2/neu en celulas cancerosas circulantes y tratamiento.

Country Status (9)

Country Link
US (2) US20080261243A1 (es)
EP (1) EP1797431B1 (es)
JP (1) JP4798801B2 (es)
CN (1) CN101036055B (es)
AT (1) ATE497165T1 (es)
CA (1) CA2582713A1 (es)
DE (1) DE602005026143D1 (es)
MX (1) MX2007004079A (es)
WO (1) WO2006041959A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005034628B4 (de) * 2005-07-19 2007-08-23 Epigenomics Ag Verfahren zur Untersuchung von Cytosin-Methylierungen in DNA
EP1803822A1 (en) * 2005-12-30 2007-07-04 Adnagen AG Method for the individual characterization of therapeutic target molecules and use thereof
US20090291920A1 (en) * 2006-04-18 2009-11-26 Wellstat Biologics Corporation Detection of steroid receptors on circulating carcinoma cells and treatment
MX2008013332A (es) * 2006-04-18 2008-11-10 Wellstat Biologics Corp Deteccion de proteinas de celulas neoplasicas circulantes.
ATE475884T1 (de) 2006-04-18 2010-08-15 Wellstat Biologics Corp Detektion von zirkulierenden endothelzellen
US20080200342A1 (en) * 2007-02-15 2008-08-21 Rao Rupa S Device, Array, And Methods For Disease Detection And Analysis
WO2008130910A1 (en) * 2007-04-19 2008-10-30 Wellstat Biologics Corporation Detection her-2/neu protein from non-isolated circulating cancer cells and treatment
KR100972618B1 (ko) * 2007-10-19 2010-07-27 국립암센터 허셉틴을 이용한 유방암 진단 키트, 조성물 및 이들을이용하여 허셉틴 민감성 ｈｅｒ２ 과발현 세포를 검출하는방법
JP5040597B2 (ja) * 2007-11-06 2012-10-03 日本電気株式会社 評価システム、評価方法および評価プログラム
EP2133433A1 (en) * 2008-06-09 2009-12-16 Centre Georges François Leclerc A method for predicting responsiveness to a treatment with an anti-HER2 antibody
CN102753193A (zh) 2008-10-31 2012-10-24 比奥根艾迪克Ma公司 Light靶向分子及其用途
WO2010070117A1 (en) * 2008-12-18 2010-06-24 Universite Libre De Bruxelles Treatment method by the administration of anti-her2 targeted active compounds to patients with early breast cancer and her2-negative primary tumor
CN101880650B (zh) * 2009-05-04 2013-01-16 卢焕梅 一种从外周血中快速提取循环的非血缘性有核细胞的组合物和试剂盒及其应用
BR112013000433A2 (pt) * 2010-07-07 2016-05-17 Univ Michigan diagnóstico e tratamento de câncer de mama
FR2976294B1 (fr) 2011-06-10 2018-02-16 Universite De Nice Sophia Antipolis Methode de prediction de la reponse a un traitement avec un agent bloquant her2
CN102830228B (zh) * 2011-06-15 2015-01-21 格诺思博生物科技(上海)有限公司 定量分析循环肿瘤细胞的试剂及试剂盒
CN104122394A (zh) * 2013-04-23 2014-10-29 北京豪迈生物工程有限公司 人表皮生长因子受体2(Her-2)定量测定试剂盒及其检测方法
CN104561246B (zh) * 2013-10-18 2018-06-15 深圳先进技术研究院 血液中循环癌细胞的检测信号放大的方法与试剂盒
CN104568923A (zh) * 2014-12-01 2015-04-29 浙江省肿瘤医院 电化学发光检测外周血循环肿瘤细胞抗原的方法及试剂盒
CN104458710B (zh) * 2014-12-09 2017-11-14 山东省海盟生化科技有限公司 肿瘤早期高通量电化学发光检测方法的构建
CN106932583A (zh) * 2015-12-29 2017-07-07 北京大成生物工程有限公司 人表皮生长因子受体Her-2/neu定量检测试剂盒及其制备方法与应用
CN106226374B (zh) * 2016-08-18 2018-10-16 中南大学 一种人类表皮生长因子受体-2浓度的检测方法
CN106319069B (zh) * 2016-09-28 2020-02-14 河南乾坤科技有限公司 一种精确测定病源细胞的试剂盒及其应用
CN111971305A (zh) * 2018-03-27 2020-11-20 美国控股实验室公司 用于鉴定可能受益于治疗剂治疗的受试者的夹心酶联免疫吸附测定
CN113366313A (zh) * 2019-01-03 2021-09-07 中尺度技术有限责任公司 实施分析测量的组合物及方法
CN111257310B (zh) * 2020-03-10 2023-05-02 莆田学院附属医院（莆田市第二医院） 一种用于癌细胞识别的电致化学发光传感器的制备方法
CN117074692B (zh) * 2023-08-15 2024-04-09 复旦大学附属华山医院 一种关于脑脊液中肿瘤细胞her2抗原表达生物信息的识别方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451225B1 (en) * 1986-04-30 2002-09-17 Igen International, Inc. Electrochemiluminescent reaction utilizing amine-derived reductant
US5401638A (en) * 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US6448091B1 (en) * 1988-11-03 2002-09-10 Igen International, Inc. Method and apparatus for improved luminescence assays using particle concentration chemiluminescence detection
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US6884357B2 (en) * 1995-02-21 2005-04-26 Iqbal Waheed Siddiqi Apparatus and method for processing magnetic particles
US5783404A (en) * 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
AU718767B2 (en) * 1995-06-07 2000-04-20 Bioveris Corporation Electrochemiluminescent enzyme immunoassay
US6117985A (en) * 1995-06-16 2000-09-12 Stemcell Technologies Inc. Antibody compositions for preparing enriched cell preparations
US6190870B1 (en) * 1995-08-28 2001-02-20 Amcell Corporation Efficient enrichment and detection of disseminated tumor cells
US6297062B1 (en) * 1996-03-07 2001-10-02 Bio-Magnetics Ltd. Separation by magnetic particles
US6890426B2 (en) * 1996-06-07 2005-05-10 Immunivest Corporation Magnetic separation apparatus and methods
DE69941689D1 (de) * 1998-02-12 2010-01-07 Univ Texas Verfahren und reagenzien zur raschen und effizienten isolierung zirkulierender krebszellen
US20020172987A1 (en) * 1998-02-12 2002-11-21 Terstappen Leon W.M.M. Methods and reagents for the rapid and efficient isolation of circulating cancer cells
WO2000047998A1 (en) * 1999-02-10 2000-08-17 Cell Works Inc. Class characterization of circulating cancer cells isolated from body fluids and methods of use
US6300143B1 (en) * 1999-03-01 2001-10-09 Idec Pharmaceuticals Corporation Electrochemiluminescent assays for eukaryotic cells
US6969615B2 (en) * 1999-07-26 2005-11-29 20/20 Genesystems, Inc. Methods, devices, arrays and kits for detecting and analyzing biomolecules
EP1231944A2 (en) * 1999-11-15 2002-08-21 University Of Southern California Targeted delivery of therapeutic and diagnostic moieties
US7537938B2 (en) * 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
AU2002306561A2 (en) * 2001-02-16 2003-09-02 Immunivest Corporation Methods and reagents for the rapid and efficient isolation of circulating cancer cells
JP3313107B2 (ja) * 2001-03-22 2002-08-12 バイエル コーポレイション ヒトの生物学的流体中のｎｅｕ関連タンパク質の検出及び定量
EP1439897B1 (en) * 2001-10-11 2010-09-01 Aviva Biosciences Corporation Methods for separating rare cells from fluid samples
JP5069843B2 (ja) * 2002-07-15 2012-11-07 ジェネンテック， インコーポレイテッド 抗ＥｒｂＢ２抗体を用いる処置に応答性である腫瘍を同定するための方法
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
EP1816477A1 (en) * 2006-02-06 2007-08-08 F. Hoffmann-la Roche AG The use of natriuretic peptides and placenta growth factor levels for risk stratification of individuals elected for cardiac stress testing
MX2008013332A (es) * 2006-04-18 2008-11-10 Wellstat Biologics Corp Deteccion de proteinas de celulas neoplasicas circulantes.
ATE475884T1 (de) * 2006-04-18 2010-08-15 Wellstat Biologics Corp Detektion von zirkulierenden endothelzellen
US20090291920A1 (en) * 2006-04-18 2009-11-26 Wellstat Biologics Corporation Detection of steroid receptors on circulating carcinoma cells and treatment

Also Published As

Publication number Publication date
CN101036055A (zh) 2007-09-12
WO2006041959A2 (en) 2006-04-20
EP1797431A2 (en) 2007-06-20
ATE497165T1 (de) 2011-02-15
WO2006041959A3 (en) 2006-06-15
HK1103439A1 (en) 2007-12-21
US20110070598A1 (en) 2011-03-24
CA2582713A1 (en) 2006-04-20
DE602005026143D1 (de) 2011-03-10
WO2006041959A8 (en) 2008-01-31
EP1797431A4 (en) 2008-07-09
JP4798801B2 (ja) 2011-10-19
JP2008517253A (ja) 2008-05-22
CN101036055B (zh) 2011-06-29
US20080261243A1 (en) 2008-10-23
EP1797431B1 (en) 2011-01-26

Similar Documents

Publication Publication Date Title
MX2007004079A (es) Detecci??n de niveles elevados de prote??na her-2/neu en celulas cancerosas circulantes y tratamiento.
Ghorbani et al. Application of various optical and electrochemical aptasensors for detection of human prostate specific antigen: A review
MX2009011228A (es) Deteccion de niveles elevados de la proteina her-2/neu de celulas cancerosas circulantes no aisladas y tratamiento.
MX2010005081A (es) Metodo para determinar la probabilidad de una respuesta terapeutica en la quimioterapia para el cancer con un glicosido cardiaco.
MX2009003562A (es) Ensayo elisa para la deteccion de vegf.
MX2021013974A (es) Metodos, sistemas y dispositivos de seleccion de pacientes tl1a.
EP2209495A4 (en) TAZ / WWTR1 FOR THE DIAGNOSIS AND TREATMENT OF CANCER
AR051524A1 (es) Seleccion de pacientes para una terapia con un inhibidor de her
MX2018009738A (es) Anticuerpos monoclonales de proteína ns1 anti-virus del dengue.
MX2021006238A (es) Metodos para tratamiento que usan terapia celular adoptiva.
ES8704005A1 (es) Un metodo para evaluar la probabilidad de malignidad celular en una muestra biologica de un haspedante humano.
AR060306A1 (es) Terapia de combinacion de anticuerpos contra ctla4
PE20151893A1 (es) Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular
AR053579A1 (es) Tratamiento de la enfermedad inflamatoria intestinal (eii)
PE20191359A1 (es) Uso de biomarcadores en la identificacion de pacientes con cancer que seran sensibles al tratamiento con un inhibidor de prmt5
CL2022002944A1 (es) Anticuerpos de unión a vista a ph ácido (solicitud divisional de 202100012)
CL2023000476A1 (es) Anticuerpos monoclonales, composiciones y métodos para detectar el factor d de complemento
WO2019178251A8 (en) Innervated intestine on chip
MX2020001958A (es) Procedimientos de diagnostico y tratamiento del cancer de pulmon.
AR084263A1 (es) Anticuerpo dirigido contra una proteina de membrana de celulas dendriticas (bdca-2) (blood dendritic cell antigen)
CL2007001748A1 (es) Compuesto derivado de 2-arilamino-4-aminopirimidinas, inhibidores de la proteina quinasa c-alfa; composiciones farmaceuticas que los contienen; y su uso para tratar o prevenir la diabetes, el cancer, enfermedades cardiovasculares y otras.
MX2017013390A (es) Método para el tratamiento de cáncer pulmonar.
BR112018012070A2 (pt) método para a produção de tecidos/ órgãos utilizando células sanguíneas
MX2018010125A (es) Procedimientos de tratamiento de leucemia mieloide aguda.
EA202192289A1 (ru) Способы мечения эукариотных клеток многоклеточного организма, а также лечения и/или диагностики рака с использованием модифицированных моносахаридных соединений

Legal Events

Date Code Title Description
FG Grant or registration